Federal eyes are finally on NAFLD. It’s about time.

In May 2024, I traveled to Washington, D.C. to meet with AHRQ Director Robert Valdez and talk about the need for the federal government to take NAFLD seriously. The American Liver Foundation and many patient advocates had been pushing for that kind of attention for years, because you cannot address a disease affecting nearly 100 million Americans if you are not even measuring it properly. That mission has been central to why I started writing here in the first place.

You cannot address a disease affecting nearly 100 million Americans if you are not even measuring it properly.

That is why AHRQ’s newly released report, Inpatient Stays Related to Nonalcoholic Fatty Liver Disease, 2016–2022, is such an important milestone. It is the first federal report of its kind focused specifically on NAFLD, and while it looks at only one part of the picture—hospitalizations—it still tells us something important. The government is finally beginning to quantify the burden of this disease.

The headline number is striking: NAFLD-related inpatient stays increased 88.1% from 2016 to 2022, rising from 370,900 to 702,500 stays. That kind of increase should be setting off alarm bells, especially for a disease that remains so poorly understood outside liver and metabolic health circles.

But the most revealing finding may be that NAFLD usually showed up as a secondary diagnosis, not the main reason a patient was admitted. In fact, hospital stays where NAFLD was the principal diagnosis stayed essentially flat, between 5,300 and 5,500 cases per year. The big increase came from patients being hospitalized for other serious conditions while NAFLD sat in the background as a coexisting disease.

That is exactly why this illness has remained so easy to miss. NAFLD often hides in plain sight. It is frequently not the headline diagnosis, but part of the larger metabolic dysfunction that contributes to a patient’s declining health over time.

AHRQ also found that 93.4% of NAFLD-related stays had at least one comorbidity, compared with 78.2% of stays without NAFLD. The most common were hypertension, obesity, and diabetes with chronic complications. Patients with secondary NAFLD were also far more likely to be hospitalized with conditions like hepatitis, hepatic failure, pancreatic disorders, obesity, and other liver disease.

NAFLD often hides in plain sight. It is frequently not the headline diagnosis, but part of the larger metabolic dysfunction that contributes to a patient’s declining health over time.

None of that is surprising to those of us who have been advocating in this space. NAFLD does not exist in isolation. It sits at the center of the broader metabolic health crisis, intersecting with obesity, diabetes, cardiovascular risk, and liver-related complications in ways the healthcare system still does a poor job of recognizing early. I have written before about the stigma surrounding liver disease and about how metabolic health conversations are often distorted by denial, confusion, and bad assumptions.

The report also found that patients with NAFLD-related stays were more likely to be between 45 and 64 years old than patients without NAFLD. That matters because it reinforces that this is not some niche condition affecting only the very old or very sick. It is hitting people in the middle of their lives, often while they are still working, raising families, and assuming that fatigue, weight gain, or abnormal labs are someone else’s problem.

For me, this report matters not just because of what it says, but because of what it represents. For years, fatty liver disease has existed in a strange policy blind spot. The prevalence is enormous, the complications are serious, and yet the public-health response has lagged badly behind. We have had growing awareness among specialists, more patient advocacy, and finally the beginning of treatment progress, but federal attention has not kept pace.

This report does not solve that problem by itself, but it does mark a turning point. Once the federal government starts measuring something, it becomes much harder to pretend it does not exist.

The American Liver Foundation recently applauded the report and said a more comprehensive AHRQ study is expected later this year. That is exactly what needs to happen next. Hospitalization data is only one slice of the story. We also need better federal data on prevalence, diagnosis, treatment, complications, and cost.

The most important takeaway here is not just that NAFLD-related hospital stays are rising sharply. It is that the federal government has finally begun to put its eyes on a disease that has remained everywhere and nowhere at the same time. That is overdue, but it is also real progress, and for patients and advocates who have been pushing for years, it is a meaningful step in the right direction.